The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

[1] FitzGerald G.A., Parsing an enigma: The pharmacodynamics of aspirin resistance, Lancet, 361, pp. 542-544, (2003)

[2] Awtry E.H., Loscalzo J., Aspirin, Circulation, 101, pp. 1206-1218, (2000)

[3] Wu K.K., Aspirin and salicylate: An old remedy with a new twist, Circulation, 102, pp. 2022-2023, (2000)

[4] Gurfinkel E.P., Altman R., Scazziota A., Heguilen R., Mautner B., Fast platelet suppression by lysine acetylsalicylate in chronic stable coronary patients Potential clinical impact over regular aspirin for coronary syndromes, Clin. Cardiol., 23, 9, pp. 697-700, (2000)

[5] Patrignani P., Filabozi P., Patrono C., Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects, J. Clin. Invest., 69, pp. 1366-1372, (1982)

[6] Reilly I.A.G., FitzGerald G.A., Inhibition of thromboxane formation in vivo and ex vivo, Blood, 69, pp. 180-186, (1987)

[7] Hoogendijk E.M.G., ten Cate J.W., Aspirin and platelets, Lancet, 1, pp. 93-94, (1980)

[8] Jakubowski J.A., Stampfer M.J., Vaillancourt R., Deykin D., Cumulative antiplatelet effect of low-dose enteric coated aspirin, Br. J. Haematol., 60, pp. 635-642, (1982)

[9] Vane J.R., Bakhle Y.S., Botting R.M., Cyclooxygenases 1 and 2, Ann. Rev. Pharmacol. Toxicol., 38, pp. 97-120, (1998)

[10] de Gaetano G., Donati M.B., Cerletti C., Prevention on thrombosis and vascular inflammation: Benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors, Trends Pharmacol. Sci., 24, pp. 245-252, (2003)

[1] FitzGerald G.A., Parsing an enigma: The pharmacodynamics of aspirin resistance, Lancet, 361, pp. 542-544, (2003)

[2] Awtry E.H., Loscalzo J., Aspirin, Circulation, 101, pp. 1206-1218, (2000)

[3] Wu K.K., Aspirin and salicylate: An old remedy with a new twist, Circulation, 102, pp. 2022-2023, (2000)

[4] Gurfinkel E.P., Altman R., Scazziota A., Heguilen R., Mautner B., Fast platelet suppression by lysine acetylsalicylate in chronic stable coronary patients Potential clinical impact over regular aspirin for coronary syndromes, Clin. Cardiol., 23, 9, pp. 697-700, (2000)

[5] Patrignani P., Filabozi P., Patrono C., Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects, J. Clin. Invest., 69, pp. 1366-1372, (1982)

[6] Reilly I.A.G., FitzGerald G.A., Inhibition of thromboxane formation in vivo and ex vivo, Blood, 69, pp. 180-186, (1987)

[7] Hoogendijk E.M.G., ten Cate J.W., Aspirin and platelets, Lancet, 1, pp. 93-94, (1980)

[8] Jakubowski J.A., Stampfer M.J., Vaillancourt R., Deykin D., Cumulative antiplatelet effect of low-dose enteric coated aspirin, Br. J. Haematol., 60, pp. 635-642, (1982)

[9] Vane J.R., Bakhle Y.S., Botting R.M., Cyclooxygenases 1 and 2, Ann. Rev. Pharmacol. Toxicol., 38, pp. 97-120, (1998)

[10] de Gaetano G., Donati M.B., Cerletti C., Prevention on thrombosis and vascular inflammation: Benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors, Trends Pharmacol. Sci., 24, pp. 245-252, (2003)